Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Woohyung Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8119-6943; OpenAlex author ID A5000792607, A5121122071, A5135629368. Sources: OpenAlex.

Their work

Papers
37 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 7 papers · 2021: 8 papers · 2022: 5 papers · 2023: 3 papers · 2024: 6 papers · 2025: 2 papers · 2026: 4 papers

Papers 37

  1. Minimally invasive vs. open-extended distal pancreatectomy with multi-organ resection: postoperative and oncological outcomes for left-sided pancreatic ductal … Co-author DOI 10.1007/s00464-025-12452-3↗
  2. Clinical outcomes of completing total pancreatectomy for isolated recurrence of pancreatic ductal adenocarcinoma in the remnant pancreas after initial pancreat… Co-author DOI 10.1016/j.surg.2026.110088↗
  3. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Co-author DOI 10.1245/s10434-026-19762-3↗
  4. Updates on Imaging Assessment of Pancreatic Cancer for Determining Anatomic and Biologic Resectability. Co-author DOI 10.3348/kjr.2026.0341↗
  5. Oncological outcomes of palliative minimally invasive distal pancreatectomy for unexpected metastatic pancreatic ductal adenocarcinoma: A single-center experie… Co-author DOI 10.1016/j.surg.2025.109331↗
  6. Taurine Synthesis by 2-Aminoethanethiol Dioxygenase as a Vulnerable Metabolic Alteration in Pancreatic Cancer. First author DOI 10.4062/biomolther.2024.086↗
  7. Computed tomography-based vascular burden index as a predictor of vascular resection and pathological vascular invasion in pancreatic cancer with neo-adjuvant … Co-author DOI 10.1016/j.ejso.2024.108494↗
  8. Reply to: "Revolutionizing pancreatic cancer management: AI-enhanced vascular burden index assessment with CT imaging". Co-author DOI 10.1016/j.ejso.2024.108576↗
  9. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000001389↗
  10. Prognostic model for resected borderline and locally advanced pancreatic cancer after neoadjuvant chemotherapy. First author DOI 10.1097/js9.0000000000001927↗
  11. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and 1… Co-author DOI 10.3348/kjr.2023.1235↗
  12. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.977↗
  13. Robotic versus laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1016/j.hbpd.2022.06.001↗
  14. Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002218↗
  15. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  16. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients. Co-author DOI 10.1016/j.ijsu.2022.106851↗
  17. A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes. Co-author DOI 10.1093/jnci/djab191↗
  18. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  19. Predictive Performance of Current Nodal Staging Systems in Various Categories of Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10641-7↗
  20. Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfron… Co-author DOI 10.21037/gs-22-304↗
  21. A comparison of minimally invasive vs open distal pancreatectomy for resectable pancreatic ductal adenocarcinoma: Propensity score matching analysis. Co-author DOI 10.1002/jhbp.853↗
  22. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-020-80383-1↗
  23. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Co-author DOI 10.1093/bjs/znab229↗
  24. Clinical Outcome of RAMPS for Left-Sided Pancreatic Ductal Adenocarcinoma: A Comparison of Anterior RAMPS versus Posterior RAMPS for Patients without Periadren… Co-author DOI 10.3390/biomedicines9101291↗
  25. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker… Co-author DOI 10.3390/biomedicines9111599↗
  26. Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location. Co-author DOI 10.3390/biomedicines9111706↗
  27. Usefulness of Inflammation-Based Prognostic Scores in Patients with Surgically Treated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm10245784↗
  28. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v13.i11.1423↗
  29. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  30. The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. Co-author DOI 10.1038/s41598-020-68703-x↗
  31. Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients. Co-author DOI 10.1097/md.0000000000022115↗
  32. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  33. Comparison of Minimally Invasive Versus Open Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Matching Analysis. Co-author DOI 10.3390/cancers12040982↗
  34. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderli… Co-author DOI 10.3390/jcm9051477↗
  35. Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm9061953↗
  36. Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s00268-016-3798-1↗
  37. Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.24133↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Song Cheol Kim · 30 shared papers, 2020–2026 · strength 4.85
  2. Ki Byung Song · 30 shared papers, 2020–2026 · strength 4.71
  3. Dae Wook Hwang · 30 shared papers, 2020–2026 · strength 4.71
  4. Yejong Park · 25 shared papers, 2020–2026 · strength 4.04
  5. Eunsung Jun · 16 shared papers, 2020–2026 · strength 2.66
  6. Kyu‐pyo Kim · 10 shared papers, 2020–2026 · strength 1.67
  7. Jaewoo Kwon · 11 shared papers, 2020–2023 · strength 1.30
  8. Min Kyu Sung · 7 shared papers, 2021–2025 · strength 1.27
  9. Baek‐Yeol Ryoo · 9 shared papers, 2020–2026 · strength 1.24
  10. Changhoon Yoo · 9 shared papers, 2020–2026 · strength 1.24
  11. Bong Jun Kwak · 8 shared papers, 2021–2024 · strength 1.22
  12. Sarang Hong · 9 shared papers, 2020–2023 · strength 1.13
  13. Seung Soo Lee · 5 shared papers, 2020–2026 · strength 1.11
  14. Dakyum Shin · 5 shared papers, 2020–2023 · strength 0.69
  15. Jin‐hong Park · 5 shared papers, 2020–2026 · strength 0.68
  16. Tae Jun Song · 5 shared papers, 2020–2026 · strength 0.68
  17. Song Cheol Kim · 3 shared papers, 2021–2025 · strength 0.59
  18. Hyoung Jung Kim · 3 shared papers, 2022–2024 · strength 0.54
  19. Dongwook Oh · 3 shared papers, 2022–2026 · strength 0.51
  20. Jae Ho Byun · 3 shared papers, 2020–2024 · strength 0.43
  21. Do Hyun Park · 4 shared papers, 2020–2023 · strength 0.43
  22. Dong Wan Seo · 4 shared papers, 2020–2023 · strength 0.43
  23. Sang Soo Lee · 4 shared papers, 2020–2023 · strength 0.43
  24. Inkeun Park · 2 shared papers, 2024–2026 · strength 0.42
  25. Kyung Hee Jung · 2 shared papers, 2022–2025 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.